Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The study is designed to determine the 32 month rate of distant relapse in patients with
uveal melanoma who are at high risk of recurrence following definitive therapy with surgery
or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and
disease specific survival in this patient population.